nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—Weight decreased—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Levonorgestrel—Pneumonia—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Levonorgestrel—Depression—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Levonorgestrel—Anorexia—Fludarabine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Levonorgestrel—Weight increased—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Levonorgestrel—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Levonorgestrel—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Levonorgestrel—Protein urine present—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Levonorgestrel—Nausea—Mechlorethamine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Levonorgestrel—Alopecia—Bleomycin—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Levonorgestrel—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Levonorgestrel—Haemoglobin—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Levonorgestrel—Urticaria—Teniposide—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Levonorgestrel—Herpes simplex—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Levonorgestrel—Haemorrhage—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Levonorgestrel—Abdominal pain—Teniposide—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Levonorgestrel—Body temperature increased—Teniposide—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Levonorgestrel—Erythema—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Levonorgestrel—Dyspnoea—Fludarabine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Levonorgestrel—Dyspepsia—Fludarabine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Levonorgestrel—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Levonorgestrel—Decreased appetite—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Levonorgestrel—Visual impairment—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Levonorgestrel—Fatigue—Fludarabine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Levonorgestrel—Pain—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Levonorgestrel—Constipation—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Levonorgestrel—Urethral disorder—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Levonorgestrel—Eye disorder—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Levonorgestrel—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Levonorgestrel—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Levonorgestrel—Hypersensitivity—Teniposide—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Levonorgestrel—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Levonorgestrel—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Levonorgestrel—Anaemia—Bleomycin—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Levonorgestrel—Asthenia—Teniposide—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Levonorgestrel—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Levonorgestrel—Pruritus—Teniposide—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Levonorgestrel—Arrhythmia—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Levonorgestrel—Cystitis—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Levonorgestrel—Cardiac disorder—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Levonorgestrel—Alopecia—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Levonorgestrel—Body temperature increased—Fludarabine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Levonorgestrel—Mental disorder—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Levonorgestrel—Vaginal infection—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Levonorgestrel—Malnutrition—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Levonorgestrel—Erythema—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Levonorgestrel—Cough—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Levonorgestrel—Diarrhoea—Teniposide—lymphatic system cancer	0.002	0.002	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Levonorgestrel—Chest pain—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Levonorgestrel—Myalgia—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Levonorgestrel—Alopecia—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Levonorgestrel—Back pain—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Levonorgestrel—Discomfort—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Levonorgestrel—Mental disorder—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Levonorgestrel—Neoplasm—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Levonorgestrel—Bladder pain—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Levonorgestrel—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Levonorgestrel—Alopecia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Levonorgestrel—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Levonorgestrel—Oedema—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Levonorgestrel—Erythema—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Levonorgestrel—Infection—Bleomycin—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Levonorgestrel—Anaemia—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Levonorgestrel—Back pain—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Levonorgestrel—Vomiting—Teniposide—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Levonorgestrel—Asthenia—Fludarabine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Levonorgestrel—Rash—Teniposide—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Levonorgestrel—Dermatitis—Teniposide—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Levonorgestrel—Headache—Teniposide—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Levonorgestrel—Pruritus—Fludarabine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Levonorgestrel—Back pain—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Levonorgestrel—Anorexia—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Levonorgestrel—Anaemia—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Levonorgestrel—Diarrhoea—Fludarabine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Levonorgestrel—Hypertension—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Levonorgestrel—Nausea—Teniposide—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Levonorgestrel—Anaemia—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Levonorgestrel—Vertigo—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Levonorgestrel—Chest pain—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Levonorgestrel—Myalgia—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Levonorgestrel—Anxiety—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Levonorgestrel—Dyspnoea—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Levonorgestrel—Hypertension—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Levonorgestrel—Oedema—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Levonorgestrel—Decreased appetite—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Levonorgestrel—Myalgia—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Levonorgestrel—Cough—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Levonorgestrel—Infection—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Levonorgestrel—Vomiting—Fludarabine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Levonorgestrel—Rash—Fludarabine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Levonorgestrel—Dermatitis—Fludarabine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Levonorgestrel—Hypertension—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Levonorgestrel—Pain—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Levonorgestrel—Headache—Fludarabine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Levonorgestrel—Myalgia—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Levonorgestrel—Chest pain—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Levonorgestrel—Anxiety—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Levonorgestrel—Discomfort—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Levonorgestrel—Oedema—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Levonorgestrel—Anorexia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Levonorgestrel—Infection—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Levonorgestrel—Nervous system disorder—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Levonorgestrel—Oedema—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Levonorgestrel—Nausea—Fludarabine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Levonorgestrel—Infection—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Levonorgestrel—Shock—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Levonorgestrel—Urticaria—Bleomycin—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Levonorgestrel—Anorexia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Levonorgestrel—Body temperature increased—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Levonorgestrel—Insomnia—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Levonorgestrel—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Levonorgestrel—Mood swings—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Levonorgestrel—Dyspnoea—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Levonorgestrel—Somnolence—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Levonorgestrel—Anorexia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Levonorgestrel—Decreased appetite—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Levonorgestrel—Insomnia—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Levonorgestrel—Pain—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Levonorgestrel—Constipation—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Levonorgestrel—Breast disorder—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Levonorgestrel—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Levonorgestrel—Decreased appetite—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Levonorgestrel—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Levonorgestrel—Somnolence—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Levonorgestrel—Fatigue—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Levonorgestrel—Asthenia—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Levonorgestrel—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Levonorgestrel—Pain—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Levonorgestrel—Constipation—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Levonorgestrel—Asthma—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Levonorgestrel—Pruritus—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Levonorgestrel—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Levonorgestrel—Fatigue—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Levonorgestrel—Pain—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Levonorgestrel—Constipation—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Levonorgestrel—Body temperature increased—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Levonorgestrel—Abdominal pain—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Levonorgestrel—Dysuria—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Levonorgestrel—Abdominal pain—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Levonorgestrel—Body temperature increased—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Levonorgestrel—Urticaria—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Levonorgestrel—Hypersensitivity—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Levonorgestrel—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Levonorgestrel—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Levonorgestrel—Pneumonia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Levonorgestrel—Vomiting—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Levonorgestrel—Infestation—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Levonorgestrel—Infestation NOS—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Levonorgestrel—Depression—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Levonorgestrel—Rash—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Levonorgestrel—Dermatitis—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Levonorgestrel—Asthenia—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Levonorgestrel—Hypersensitivity—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Levonorgestrel—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Levonorgestrel—Asthenia—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Levonorgestrel—Diarrhoea—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Levonorgestrel—Nausea—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Levonorgestrel—Asthenia—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Levonorgestrel—Dizziness—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Levonorgestrel—Diarrhoea—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Levonorgestrel—Pharyngitis—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Levonorgestrel—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Levonorgestrel—Vomiting—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Levonorgestrel—Dizziness—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Levonorgestrel—Rash—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Levonorgestrel—Dermatitis—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Levonorgestrel—Visual impairment—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Levonorgestrel—Headache—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Levonorgestrel—Vomiting—Vincristine—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000996	0.000996	CcSEcCtD
Levonorgestrel—Rash—Vincristine—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Levonorgestrel—Dermatitis—Vincristine—lymphatic system cancer	0.00099	0.00099	CcSEcCtD
Levonorgestrel—Headache—Vincristine—lymphatic system cancer	0.000985	0.000985	CcSEcCtD
Levonorgestrel—Nausea—Carmustine—lymphatic system cancer	0.000978	0.000978	CcSEcCtD
Levonorgestrel—Vomiting—Mitoxantrone—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Levonorgestrel—Rash—Mitoxantrone—lymphatic system cancer	0.000965	0.000965	CcSEcCtD
Levonorgestrel—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Levonorgestrel—Headache—Mitoxantrone—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—lymphatic system cancer	0.00094	0.00094	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Levonorgestrel—Nausea—Vincristine—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Levonorgestrel—Nausea—Mitoxantrone—lymphatic system cancer	0.000909	0.000909	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Levonorgestrel—Anaemia—Methotrexate—lymphatic system cancer	0.000864	0.000864	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Levonorgestrel—Cough—Methotrexate—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Levonorgestrel—Discomfort—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Levonorgestrel—Infection—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000748	0.000748	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—lymphatic system cancer	0.000741	0.000741	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—lymphatic system cancer	0.000727	0.000727	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000695	0.000695	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—lymphatic system cancer	0.00068	0.00068	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000658	0.000658	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—lymphatic system cancer	0.000652	0.000652	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Levonorgestrel—Urticaria—Methotrexate—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000562	0.000562	CcSEcCtD
Levonorgestrel—Asthenia—Methotrexate—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—lymphatic system cancer	0.00054	0.00054	CcSEcCtD
Levonorgestrel—Diarrhoea—Methotrexate—lymphatic system cancer	0.000522	0.000522	CcSEcCtD
Levonorgestrel—Dizziness—Methotrexate—lymphatic system cancer	0.000504	0.000504	CcSEcCtD
Levonorgestrel—Vomiting—Methotrexate—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Levonorgestrel—Rash—Methotrexate—lymphatic system cancer	0.000481	0.000481	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—lymphatic system cancer	0.00048	0.00048	CcSEcCtD
Levonorgestrel—Headache—Methotrexate—lymphatic system cancer	0.000478	0.000478	CcSEcCtD
Levonorgestrel—Nausea—Methotrexate—lymphatic system cancer	0.000453	0.000453	CcSEcCtD
